Table 2.
Properties of preclinical and clinical CD47 antibodies and related inhibitors of CD47 function
| Antibody Name | Source | Origin | Isotype | Specificity | CD47/SIRPα blockade | Agonist activity |
|---|---|---|---|---|---|---|
| MIAP301 | Research | rat | IgG2a | muCD47 | Yes | |
| A4 | Research | Alpaca | Nanobody | muCD47 | Yes | |
| A4-Fc | Research | Fusion | IgG2a | nuCD47 | Yes | |
| OX101 | Research | Mouse | IgG1 | ratCD47 | Yes | |
| B6H12 | Research | Mouse | IgG1 | huCD47 | Yes | Yes/No |
| 2D3 | Research | Mouse | IgG1 | huCD47 | No | |
| Vx1000R | Arch Oncology | Mouse | huCD47 | Yes | ||
| MAB4670 | Research | Mouse | IgG1 | huCD47 | Yes | |
| BRIC126 | Research | Mouse | IgG2b | huCD47 | Yes | Yes/No |
| CC2C6 | Research | Mouse | IgG1 | huCD47 | Yes | Yes |
| 1F7 | Research | Mouse | IgG1 | huCD47 | Yes | |
| Ad22 | Research | Mouse | IgG1 | huCD47 | Yes | |
| mAb400 | Research | Mouse | IgG2a | hu/muCD47 | Yes | |
| MIAP410 | Research | Mouse | IgG1 | hu/muCD47 | Yes/No | |
| MABL sc(Fv)2 | Research | Mouse | (scFv)2 | huCD47 | Yes | |
| MABL scFv | Research | Mouse | scFv | huCD47 | No | |
| Hu5F9-G4 | 47/Gilead | Humanized | IgG4 | huCD47 | Yes | |
| AO-176 | Arch Oncology | Humanized | IgG2 | huCD47 | Yes | Yes |
| AO-104 | Arch Oncology | Humanized | IgG4 | huCD47 | Yes | |
| SRF231 | Surface Oncology | Fully human | IgG4 | huCD47 | Yes | |
| SHR-1603 | Hengrui | Humanized | IgG4 | huCD47 | Yes | |
| CC90002 | Celgene | Humanized | IgG4 | huCD47 | Yes | |
| HuNb1 | Shanghai Novamab | Camel VHH-fusion | IgG4 | huCD47 | Yes | |
| C47B | Janssen | Fully human | IgG1 | huCD47 | Yes | |
| IBI188 | Innovent | Fully human | IgG4 | huCD47 | Yes | |
| ZF1 | Beijing Inst. of Biotechnology | Fully human | IgG1 | huCD47 | Yes | |
| AMMS4-G4 | Beijing Inst. of Biotechnology | Fully human | IgG4 | huCD47 | Yes | |
| h4C1 | CAS Key Laboratory | Humanized | huCD47 | Yes | ||
| CD47xPD-L1 | CAS Key Laboratory | bsAb from h4C1 | IgG4 | CD47xPD-L1 | Yes | |
| IBI-322 | Innovent | bsAb | CD47xPD-L1 | Yes | ||
| HX-009 | Waterstone Hanxbio | bsAb | CD47xPD1 | Yes | ||
| CD47xMSLN | Novimmune | bsAb | IgG1 | CD47xMSLN | Yes | |
| OV-TL3/CD3 | research | bsAb F(ab’)2 | No Fc | CD47xCD3 | ? | |
| CD47xEGFR | Xinxiang Medical University | SIRPαV-bsAb | IgG1 | CD47xEGFR | Yes | |
| HuNb1-rituximab | Shanghai Novamab | Bispecific scFv | No Fc | CD47xCD20 | Yes | |
| RTX-CD47 | University of Groningen | Tandem-scFv | No Fc | CD47xCD20 | Yes | |
| TG-1801 | TG Therapeutics | Fully human bsAb | IgG1 | CD47xCD19 | Yes | |
| CC-95251 | Celgene | Humanized | huSIRPα | Yes | ||
| OSE-172 | OSE Immunotherapeutics | huSIRPα | Yes | |||
| TTI-621 | Trillium | SIRPα fusion | IgG1 | huCD47 | Yes | |
| TTI-622 | Trillium | SIRPα fusion | IgG4 | huCD47 | Yes | |
| ALX148 | Alexo | SIRPα-Fc* fusion | Inactive | huCD47 | Yes |